Natco Pharma Share Price Target 2026, 2027, 2028, 2029, 2030

Natco Pharma share price today

Natco Pharma (NSE: NATCOPHARM) is the special-situations specialist of Indian pharma — the company that challenges patents (Para-IV filings), wins first-to-file windfalls, and books profits in lumps that make its quarterly chart look like a seismograph. Its greatest hit, generic Revlimid in the US, produced two windfall years. That windfall is now ending, everyone knows it, and the stock trades at 11.6 times earnings and 1.78 times book.

The question that decides everything: is this a value trap (earnings cliff, cheap for a reason) or a coiled spring (the next catalysts already funded and filed)? Both cases are strong. Here is the arithmetic for each.

The model: hunt windfalls, bank them, repeat

Natco does not sell volume generics. It files patent challenges on complex, high-value drugs, partners with US majors (Teva, Lupin, Dr. Reddy’s, Alvogen), and shares the exclusivity profits when it wins. Between windfalls it runs domestic oncology, a crop-health science business (chlorantraniliprole), APIs and emerging-market formulations.

The consequence is structural lumpiness — look at the last four quarters: profits of ₹480 Cr, ₹518 Cr, ₹151 Cr, ₹269 Cr. Anyone demanding smooth quarters should not own this stock; anyone pricing it on one quarter, in either direction, is doing it wrong.

The cliff, visible in the annual numbers

From Screener.in, consolidated:

Year	Sales (₹ Cr)	OPM	Net profit (₹ Cr)	EPS (₹)
FY23	2,707	35%	715	39.18
FY24	3,999	44%	1,388	77.51
FY25	4,430	50%	1,883	105.26
FY26	4,078	35%	1,418	79.20

FY25 was the Revlimid peak; FY26 is the descent beginning — sales −8%, profit −25%. The US Revlimid opportunity fades to a tail as full genericisation arrives. The 11.6× multiple is not on peak earnings; it is on post-peak earnings that the market assumes keep falling. That assumption is the entire debate.

What Natco bought with the windfall

This is the part the cliff-watchers miss — the balance sheet redeployment is already happening:

• Adcock Ingram, South Africa’s #2 pharma company: Natco now owns 49%, after investing roughly ₹2,300 Cr across 2025–26 (the final 13.25% block completed in July 2026). This converts windfall cash into a durable, cash-generating consumer-pharma earnings stream.
• The semaglutide prize: the blockbuster diabetes/obesity molecule came off patent in India in 2026, and Natco is in the first wave with vertically integrated API plus filings across emerging markets and (with partners) regulated ones. Nobody knows the exact size; everybody knows the market is enormous.
• Pipeline shots: tentative US approval for generic olaparib arrived in July 2026 (litigation ongoing) — classic Natco: file, litigate, wait, collect.
• Net of it all: ₹3,127 Cr of investments on the books, borrowings of just ₹714 Cr, FY26 free cash flow of ₹1,379 Cr.

Shareholding

Promoters (the Nannapaneni family) hold 49.4%, drifting down only marginally over years. FIIs hold 17%, and the public share has risen to 28% — four lakh shareholders now own a piece of the lumpiest compounder in pharma. No pledge.

Natco Pharma share price target 2026 to 2030

EPS base ₹79.20 (FY26). Bear: the Revlimid tail vanishes faster than new launches replace it — EPS grinds down to ~₹55 by 2030, and a value-trap 9× applies: ₹495. Base: semaglutide plus Adcock consolidation plus the oncology/crop base roughly offset the cliff and grow modestly — EPS ~₹95 at 12×: ₹1,140. Bull: semaglutide scales across markets while another Para-IV hits — EPS ~₹130 at 15×: ₹1,950.

Year	Bear (9×, cliff wins)	Base (12×, catalysts offset)	Bull (15×, next windfall)
2026	₹830	₹1,000	₹1,150
2027	₹760	₹1,030	₹1,330
2028	₹690	₹1,070	₹1,530
2029	₹590	₹1,100	₹1,740
2030	₹495	₹1,140	₹1,950

From ₹921 the base case is ~+24% by 2030 — modest, because the base assumes the catalysts merely offset the cliff. The real attraction is the skew: at 1.78× book with ₹3,100 Cr of investments and net cash, the bear case is cushioned by assets, while either semaglutide scaling or one more Para-IV win rewrites the bull column overnight. This is a stock you size for the skew, not the certainty.

Reasons Natco is in our research universe

1. 11.6× earnings, 1.78× book, EV/EBITDA 9 — the cliff is priced; the catalysts largely are not.
2. Semaglutide, first wave, vertically integrated — a legitimate shot at the decade’s biggest generic opportunity.
3. 49% of Adcock Ingram — windfall cash converted into a durable second earnings base, not buybacks and vanity.
4. Serial windfall-hunter with a 25-year record: Revlimid was not the first and is unlikely to be the last.
5. Near-zero debt, ₹1,379 Cr FCF, promoter at 49.4% unpledged.
6. PEG 0.44 on its five-year record — even after the FY26 decline.

Risks, plainly: the cliff is certain while the catalysts are probabilistic; quarterly lumpiness will repeatedly look like collapse; semaglutide pricing could race to the bottom fast; Adcock brings currency and integration risk; and a low tax rate flattered FY26’s bottom line.

Should you buy at the current price?

The live buy range below is for members — the exact accumulation zone, updated as our view changes.

FAQ

What is the Natco Pharma share price target for 2030? Base case ≈ ₹1,140 (12× on EPS recovering to ~₹95 as catalysts offset the Revlimid cliff), bear ≈ ₹495, bull ≈ ₹1,950. Arithmetic above.

Why is Natco Pharma so cheap? Its biggest profit engine (US generic Revlimid) is winding down — FY26 profit fell 25%. The market extrapolates the decline; the debate is whether semaglutide, Adcock Ingram and the pipeline replace it.

What is Natco’s semaglutide opportunity? The diabetes/obesity blockbuster lost Indian patent protection in 2026. Natco is among the first-wave launchers with its own API — the opportunity spans India and emerging markets, with partnered regulated-market filings behind it.

What did Natco buy in South Africa? A 49% stake in Adcock Ingram, South Africa’s second-largest pharma company, built through 2025–26 for roughly ₹2,300 Cr — redeploying windfall cash into durable earnings.

When are Natco’s next results? Q1 FY27 lands in mid-August 2026 — track it on our results calendar. Expect lumpiness; judge the year, not the quarter.

---

This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises — patent litigation, drug pricing and market shocks can push prices outside every band shown. Do your own research and consult a registered adviser before acting.